Assessment of PSA relapse after curative treatment of prostate cancer;Einschätzung des PSA-rezidivs nach kurativer therapie des prostatakarzinoms

Journal fur Urologie und Urogynakologie

Volumn 11, Issue SUPPL. 3, 2004, Pages 3-11

  Weißbach, Lothar ^a   Sedlmayer, Felix ^b  

^a Urologische Partnerschaft   (Germany)

^b Landesklinik für Radiotherapie und Radioonkologie ^*  (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 20444451865     PISSN: 10236090     EISSN: 16809424     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am 2003; 30: 377-401.
2. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncology 2004; 5: 101-6.
3. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7.
4. Koch MO, Foster RS, Bell B, et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J. Urol 2000; 164: 749-53.
5. Shah O, Melamed J, Lepor H. Analysis of apical soft tissue margins during radical retropubic prostatectomy. J Urol 2001; 165: 1943-9.
6. Lepor H, Chan S, Melamed J. The role of bladder neck biopsy in men undergoing radical retropubic prostatectomy with preservation of the bladder neck. J Urol 1998; 160: 2435-9.
7. Partin AW, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1994; 152: 172-3.
8. Nelson JB, Lepor H. Prostate cancer: radical prostatectomy. Urol Clin North Am 2003; 30: 703-23.
9. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-41.
10. Critz FA, Williams WH, Holladay CT, et al. Posttreatment PSA ≤ 0.2 ng/ml defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 1999; 54: 968-71.
11. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281: 1598-604.
12. Pollack A, Horwitz EM, Movsas B, Hanlon AL. Mindless or mindful? Radiation oncologists' perspectives on the evaluation of prostate cancer treatment. Urol Clin North Am 2003; 30: 337-49.
13. D'Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131-8.
14. Epstein JI, Partin AW, Sauvegeot J, Walsh PC. Prediciton of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20: 286-92.
15. Laufer M, Pound CR, Carducci MA, Eisenberger MA. Management of patients with rising PSA after radical prostatectomy. Urology 2000; 55: 309-15.
16. Ohori M, Wheeler TM Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive margins in radical prostatectomy specimens. J Urol 1995; 154: 1818-24.
17. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406.
18. Gretzer MB, Trock BJ, Han M, Walsh PC. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 2002; 168: 1419-22.
19. Wiegel T, Miller K, Heicappell R, Steiner U, et al. Strahlentherapie nach radikaler Prostatektomie bei PSA-Anstieg aus dem "Nullbereich" ohne histologische Sicherung eines Lokalrezidivs - eine kurative Therapieoption? Akt Urol 2001; 32: 160-4.
20. Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: recommendations from the PSA working group. J Clin Oncol 2004; 22: 537-56.
21. Leventis AK, Shariat SF, Kattan MW, et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001; 19: 1030-9.
22. Patel A, Dorey F, Franklin J. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158: 1441-5.
23. Shekarriz B, Upadhyay J, Wood DP, et al. Vesicourethral anastomosis biospsy after radical prostatectomy: predictive value of PSA an pathologic stage. Urology 1999; 54: 1044-8.
24. Scattoni V, Roscigno M, Raber M, et al. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003; 44: 407-14.
25. Fowler JE, Brooks J, Pandey P, Seaver LE. Prostate cancer: variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995; 153: 1011-4.
26. Zelefsky M, Fuks Z, Hunt M, et al.. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166: 876-81.
27. Crook J, Perry G, Robertson S, Esche B. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995; 45: 624-32.
28. Johnstone P, McFarland J, Riffenburg R, Amling C. Efficacy of digital rectal examination after radiotherapy for prostate cancer. J Urol 2001; 166: 1684-7.
29. Almroth A, Ljung G, Eklund T et al. Value of sextant biopsies in the assessment of local cure following external beam radiotherapy of prostatic adenocarcinoma. Scand J Urol Nephrol 1998; 32: 111-5.
30. Borghede G, Aldenborg F, Wurzinger E, et al. Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy. Br J Urol 1997; 80: 247-55.
31. Pollack A, Zagars G, Antolak J, Kuban D, Rosen I. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002; 54: 677.
32. Lukka H, Hayter C, Jones E, et al. Assessment of post-radiation prostatic needle biopsies for residual adenocarcinoma: a study of interobserver agreement (abstract). Radiother Oncol 2002; 65: 13.
33. Zelefsky M, Liebel S, Gaudin P, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491-500.
34. Cox J, Gallagher M, Hammond E, et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology consensus panel. J Clin Oncol 1999; 17: 1155.
35. Sella T, Schwarth LH, Swindle PW, et al. Endorectal coil MR in patients with suspected local recurrence following prostatectomy. Am J Radiol (in press).
36. Chybowski FM, Keller JJL, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1994; 145: 313-8.
37. Cher ML, Bianco FJ, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998; 160: 1387-91.
38. Lee CT, Oesterling JE. Using prostate-specific antigen to eliminate the stageing radionuclide bone scan. Urol Clin North Am 1997; 24: 389-94.
39. Kao CH, Hsieh JF, Tsai SC, et al. Comparsion and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20: 2189-92.
40. Oyama N, Miller TR, Dehdashti F, et al. Carbon-11-Acetate PET imaging of recurrent prostate cancer. J Urol 2002; 167: Abstract 697.
41. Waldert M, Kurtaran A, Djavan B, Marberger M. Die Europäische Multicenter Evaluation der Carbon-11-Acetat Positronen-emissionstomographie bei Männern mit PSA-Anstieg nach radikaler Prostatektomie. 55. Kongreß DGU 2003; V8.9.
42. Picchio M, Messa C, Landoni C, et al. Value of 11-C-choline-positron- emission-tomography for restaging prostate cancer: a comparison with 18F-fluordeoxyglucose-positron emissiontomography. J Urol 2003; 169: 1337-40.
43. Sartor O, McLeod D. Indium-111-capromab pendetide scans: An important test relevant to clinical decision making. Urology 2001; 57: 399-401.
44. Hinkle G, Burgers J, Neal C, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using Indium-111 capromab pendetide. Cancer 1998; 83: 739-47.
45. Cannon GM, Walsh PC, Partin AW, Pound CR. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urology 2003; 62 (Suppl 6B): 2-8.
46. D'Amico AV, Cote K, Loffredo M, et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20: 4567-73.
47. Roberts SG, Blute ML, Bergstralh EJ, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001; 76: 576-81.
48. Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Sem Urol Oncol 2002; 20: 108-15.
49. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 1821-5.
50. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for prediction tumor biology and clinical outcome in prostate cancer. Cancer 1993; 72: 2638-43.
51. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997; 15: 230-8.